Could CDK4/6 inhibitors be a standard of care for advanced breast cancer?

  • Identify suitable patients with advanced breast cancer to try CDK4/6 inhibitors
  • Learn the latest CDK4/6 inhibitor survival data from our breast cancer experts
  • Optimally manage CDK4/6 inhibitor safety in your patients

CDK4/6 inhibitor clinical trials in advanced breast cancer

The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) abemaciclib, palbociclib, and ribociclib have been approved by the FDA and the EMA for the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC).

Login to Medthority to view this content, or register an account.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.